Like many 37-year-olds, Eric Holdt strives to savor life’s moments. Yet what sets him apart is his daily battle with Type 1 diabetes. Living with a disease in which the body’s immune system attacks the pancreas, reducing its ability to produce insulin, Holdt has faced the challenge of managing his blood sugar levels. But recently, he became one of the first recipients in Nebraska and Iowa to undergo groundbreaking Tzield monoclonal antibody treatment. most,” Holdt said. Tzield, a monoclonal antibody treatment, aims to combat type 1 diabetes at its onset, potentially delaying the need for insulin. Holdt described the process as simple and simplified. Miranda Kuhr, Holdt’s pharmacist, explained the potentially transformative nature of Tzield “We noticed that after or even during treatment, their blood sugar levels went down by about 40%, which is incredible. “, Kuhr said. Additionally, Kuhr expressed hope that this new treatment would allow more people with type 1 diabetes to lead happier, healthier lives. “It is only approved for use lifetime, and we hope it will delay the need for insulin by three to 10 years,” she said. While Tzield offers new optimism to type 1 diabetes patients, Holdt’s story is a glimmer of hope, illustrating the potential of medical advances to improve quality of life Holdt said this treatment is a breakthrough for him and countless others Click here for the latest headlines from KETV NewsWatch 7.
Like many 37-year-olds, Eric Holdt strives to savor life’s moments. But what sets him apart is his daily battle with type 1 diabetes.
Living with a disease in which the immune system attacks the pancreas, reducing its ability to produce insulin, Holdt faced the challenge of managing his blood sugar levels. But recently, he became one of the first recipients in Nebraska and Iowa to undergo groundbreaking Tzield monoclonal antibody treatment.
“I haven’t had any bad reactions or anything like that. I’ve been able to keep my blood sugar pretty normal for the most part,” Holdt said.
Tzield, a monoclonal antibody treatment, aims to fight type 1 diabetes from its onset, potentially delaying the need for insulin. Holdt described the process as streamlined and simple.
Miranda Kuhr, Holdt’s pharmacist, dismantled the potentially transformative nature of Tzield.
“We noticed that after or even during treatment, their blood sugar dropped by about 40%, which is incredible,” Kuhr said.
Additionally, Kuhr expressed hope that this new treatment would allow more people with type 1 diabetes to lead happier, healthier lives.
“It is only approved for one-time, lifetime use, and we hope it will delay the need for insulin by three to 10 years,” she said.
As Tzield offers new optimism to Type 1 diabetes patients, Holdt’s story serves as a beacon of hope, illustrating the potential of medical advances to improve quality of life.
Holdt said this treatment is a breakthrough for him and countless others.
Click here for the latest headlines from KETV NewsWatch 7
News Source : www.ketv.com
Gn Health
